Donor chimerism after HSCT. The percentage of patients achieving full donor chimerism (> 95% donor cells) for CD3⁺- and CD33⁺-enriched cells at day +30, +100, +180, and +365 after HSCT. Patients with relapse or progressive disease were excluded.